eMedicine Specialties > Dermatology > Mycobacterial Infections

Mycobacterium Marinum Infection of the Skin

Author: Joslyn S Kirby, MD, Assistant Professor, Department of Dermatology, Milton S Hershey Penn State Medical Center
Coauthor(s): Ellen J Kim, MD, Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania; Saeed Jaffer, MD, MS, Assistant Clinical Professor, University of California at Los Angeles School of Medicine, Consulting Staff, Boston Dermatology
Contributor Information and Disclosures

Updated: Jul 13, 2009

Introduction

Background

Mycobacterium marinum is an atypical Mycobacterium found in salt water and fresh water. M marinum is the most common atypical Mycobacterium to cause infection in humans. Infection occurs following inoculation of a skin abrasion or puncture and manifests as a localized granuloma or sporotrichotic lymphangitis. Diagnosis and treatment are often delayed because of a lack of suspicion for mycobacterial involvement, ie, versus more common bacterial pathogens. Due to the regular use of tumor necrosis factor (TNF) inhibitors for various conditions and immunosuppressants for transplant recipients, infections with mycobacteria other than tuberculosis (MOTT) are increasing.

Pathophysiology

M marinum infection occurs following trauma to an extremity that is in contact with an aquarium, salt water, or marine animals such as fish or turtles. Exposure to M marinum via swimming pools is rare because most pools are chlorinated.

The pathogen is classified in Runyon group 1 and is a photochromogen, which means it produces yellow pigment when cultured and exposed to light. Culture growth occurs over 7-21 days and is optimal at 25-32°C (77-89.6°F) because the organism is adapted to infect ectotherms, such as fish. Endotherms, such as humans, also can be infected; the cooler extremities are affected more often than central sites. Systemic infection, usually in the context of an immunocompromised host, has been reported. This indicates that the organism is capable of adapting to grow in conditions closer to 37°C.1

After inoculation into the host tissues via an abrasion or other wound, the mycobacteria are phagocytosed by macrophages. Inside the macrophage, they are able to interrupt the formation of the phagolysosome, which would kill the organisms. The mycobacteria then escape the lysosome and can move intracellularly and extracellularly via actin-based motility. This may contribute to cell-to-cell spread.

TNF is important for the immune response against mycobacteria. Studies have demonstrated that in the absence of TNF, macrophages engulf but do not destroy the mycobacteria. Instead, the mycobacteria survive and grow, finally killing the macrophage.2

Studies have revealed 2 pathophysiologically and genetically (ie, via amplified restriction-based polymorphism analysis) distinct populations of M marinum. One group can infect humans and causes acutely lethal disease in fish, while a second group cannot infect humans and causes chronic progressive disease in fish.

Frequency

United States

Infections caused by M marinum are uncommon but well described in the literature. The estimated annual incidence is 0.27 cases per 100,000 adult patients. Of the approximately 160 cases described, most are case reports of cutaneous infection; however, some have concomitant osteomyelitis, tenosynovitis, arthritis, and/or disseminated infection. Nosocomial infection has never been described.

International

Infection occurs worldwide, most commonly in individuals with occupational and recreational exposure to fresh or salt water.

Mortality/Morbidity

M marinum skin infection typically remains localized and does not cause significant morbidity in patients who are immunocompetent. Cases reported in patients who are severely immunocompromised have resulted in disseminated infection involving the bone marrow and viscera and may result in death.

Race

No racial predilection is apparent for M marinum skin infection.

Sex

No sexual predilection has been noted for M marinum skin infection.

Age

M marinum infection has been reported in persons of every age group; however, it appears to be rare in the pediatric population.3

Clinical

History

  • Patients at risk include anglers (commercial, recreational), oyster workers, swimmers, aquarium workers, and individuals with aquariums in their homes. Infection has also been reported following natural disasters involving the ocean.4
  • Patients may present with a papule, nodule, or ulcer at the site of trauma and a history of exposure to nonchlorinated water 2-3 weeks earlier. Patients may give a history of a papule or nodule that subsequently ulcerated and/or (1) signs of the infection spreading up the finger or hand or (2) involvement of the local joint or tendons. Over a period of months, localized cutaneous disease can spread to soft tissues.
  • Localized pain and induration are common. Fever, lymphadenopathy, and systemic infection are rare, with the exception of in immunosuppressed patients.

Physical

  • An erythematous or bluish 0.5- to 3-cm papule or nodule develops at the inoculation site. Ulceration can occur later, and subsequent lesions may be present along the path of lymphatic drainage of the extremity. This occurs in 25-50% of patients and is termed sporotrichotic spread.
  • The upper extremity is the inoculation site in 90% of cases.
  • Lymphadenopathy may be present.
  • Patients may have deeper involvement, with tenosynovitis, bursitis, septic arthritis, and osteomyelitis of the underlying bone. Dissemination to the bone marrow and abdominal viscera is rare.
  • If diagnosis is delayed, the infections can mimic rheumatoid arthritis, gout, trauma-related tenosynovitis, foreign body, deep fungal infections, or malignancy.

Causes

The cause is infection with M marinum.

  • Exposure of traumatized skin to affected aqueous environments (fish tanks) is the leading predisposing factor.
  • Individuals who are consistently exposed to the organism are more likely to develop the infection.
  • Hosts who are immunocompromised are also at increased risk.

More on Mycobacterium Marinum Infection of the Skin

Overview: Mycobacterium Marinum Infection of the Skin
Differential Diagnoses & Workup: Mycobacterium Marinum Infection of the Skin
Treatment & Medication: Mycobacterium Marinum Infection of the Skin
Follow-up: Mycobacterium Marinum Infection of the Skin
References

References

  1. Kent ML, Watral V, Wu M, Bermudez LE. In vivo and in vitro growth of Mycobacterium marinum at homoeothermic temperatures. FEMS Microbiol Lett. Apr 2006;257(1):69-75. [Medline].

  2. Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. Aug 15 2008;29(2):283-94. [Medline].

  3. Doedens RA, van der Sar AM, Bitter W, Scholvinck EH. Transmission of Mycobacterium marinum from fish to a very young child. Pediatr Infect Dis J. Jan 2008;27(1):81-3. [Medline].

  4. Appelgren P, Farnebo F, Dotevall L, Studahl M, Jonsson B, Petrini B. Late-onset posttraumatic skin and soft-tissue infections caused by rapid-growing mycobacteria in tsunami survivors. Clin Infect Dis. Jul 15 2008;47(2):e11-6. [Medline].

  5. S Breza T Jr, Magro CM. Lichenoid and granulomatous dermatitis associated with atypical mycobacterium infections. J Cutan Pathol. Jul 2006;33(7):512-5. [Medline].

  6. Lam A, Toma W, Schlesinger N. Mycobacterium marinum arthritis mimicking rheumatoid arthritis. J Rheumatol. Apr 2006;33(4):817-9. [Medline].

  7. Gluckman SJ. Mycobacterium marinum. Clin Dermatol. May-Jun 1995;13(3):273-6. [Medline].

  8. Bhambri S, Bhambri A, Del Rosso JQ. Atypical mycobacterial cutaneous infections. Dermatol Clin. Jan 2009;27(1):63-73. [Medline].

  9. Wongworawat MD, Holtom P, Learch TJ, Fedenko A, Stevanovic MV. A prolonged case of Mycobacterium marinum flexor tenosynovitis: radiographic and histological correlation, and review of the literature. Skeletal Radiol. Sep 2003;32(9):542-5. [Medline].

  10. Mahaisavariya P, Chaiprasert A, Manonukul J, Khemngern S, Tingtoy N. Detection and identification of Mycobacterium species by polymerase chain reaction (PCR) from paraffin-embedded tissue compare to AFB staining in pathological sections. J Med Assoc Thai. Jan 2005;88(1):108-13. [Medline].

  11. Ho MH, Ho CK, Chong LY. Atypical mycobacterial cutaneous infections in Hong Kong: 10-year retrospective study. Hong Kong Med J. 2006/January;12:21-6.

  12. Nolte O, Haag H, Hafner B. A mutation in the 65,000 Dalton heat shock protein gene, commonly used for molecular identification of non-tuberculous mycobacteria, leads to the misidentification of Mycobacterium malmoense as Mycobacterium marinum. Mol Cell Probes. Aug 2005;19(4):275-7. [Medline].

  13. Rybniker J, Kramme S, Small PL. Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis--application for identification and susceptibility testing. J Med Microbiol. Jan 2006;55:37-42. [Medline].

  14. Travis WD, Travis LB, Roberts GD, Su DW, Weiland LW. The histopathologic spectrum in Mycobacterium marinum infection. Arch Pathol Lab Med. Dec 1985;109(12):1109-13. [Medline].

  15. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother. Dec 2007;8(17):2965-78. [Medline].

  16. Bhatty MA, Turner DP, Chamberlain ST. Mycobacterium marinum hand infection: case reports and review of literature. Br J Plast Surg. Mar 2000;53(2):161-5. [Medline].

  17. Cummins DL, Delacerda D, Tausk FA. Mycobacterium marinum with different responses to second-generation tetracyclines. Int J Dermatol. Jun 2005;44(6):518-20. [Medline].

  18. Dodiuk-Gad R, Dyachenko P, Ziv M, et al. Nontuberculous mycobacterial infections of the skin: A retrospective study of 25 cases. J Am Acad Dermatol. Sep 2007;57(3):413-20. [Medline].

  19. Janik JP, Bang RH, Palmer CH. Case reports: successful treatment of Mycobacterium marinum infection with minocycline after complication of disease by delayed diagnosis and systemic steroids. J Drugs Dermatol. Sep-Oct 2005;4(5):621-4. [Medline].

  20. Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med. Jun 27 1994;154(12):1359-64. [Medline].

  21. Garcia-Rodriguez JA, Gomez Garcia AC. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother. Dec 1993;32(6):797-808. [Medline].

  22. Jernigan JA, Farr BM. Incubation period and sources of exposure for cutaneous Mycobacterium marinum infection: case report and review of the literature. Clin Infect Dis. Aug 2000;31(2):439-43. [Medline].

  23. Ljungberg B, Christensson B, Grubb R. Failure of doxycycline treatment in aquarium-associated Mycobacterium marinum infections. Scand J Infect Dis. 1987;19(5):539-43. [Medline].

  24. Noguchi M, Taniwaki Y, Tani T. Atypical Mycobacterium infections of the upper extremity. Arch Orthop Trauma Surg. Sep 2005;125(7):475-8. [Medline].

  25. Noonburg GE. Management of extremity trauma and related infections occurring in the aquatic environment. J Am Acad Orthop Surg. Jul-Aug 2005;13(4):243-53. [Medline].

  26. Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. Jun 2005;133(3):383-91. [Medline].

  27. Ryan JM, Bryant GD. Fish tank granuloma--a frequently misdiagnosed infection of the upper limb. J Accid Emerg Med. Nov 1997;14(6):398-400. [Medline].

  28. Stamm LM, Brown EJ. Mycobacterium marinum: the generalization and specialization of a pathogenic mycobacterium. Microbes Infect. Dec 2004;6(15):1418-28. [Medline].

Further Reading

Keywords

mycobacterial skin infection, fish tank granuloma, tropical fish tank granuloma, M marinum, Mycobacterium, Mycobacterium marinum, mycobacteria other than tuberculosis, MOTT, nontuberculous mycobacteria, mycobacteria, acid-fast mycobacteria, saltwater infection, freshwater infection, marine infection, marine bacteria, water-borne bacteria, water-borne bacterial infection

Contributor Information and Disclosures

Author

Joslyn S Kirby, MD, Assistant Professor, Department of Dermatology, Milton S Hershey Penn State Medical Center
Joslyn S Kirby, MD is a member of the following medical societies: American Academy of Dermatology, International Society for Cutaneous Lymphomas, Pennsylvania Academy of Dermatology, and Women's Dermatologic Society
Disclosure: Nothing to disclose.

Coauthor(s)

Ellen J Kim, MD, Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Ellen J Kim, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Dermatology Foundation, Medical Dermatology Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Saeed Jaffer, MD, MS, Assistant Clinical Professor, University of California at Los Angeles School of Medicine, Consulting Staff, Boston Dermatology
Saeed Jaffer, MD, MS is a member of the following medical societies: American Academy of Dermatology and American Society for MOHS Surgery
Disclosure: Nothing to disclose.

Medical Editor

Terry L Barrett, MD, Clinical Professor of Dermatology and Pathology, University of Texas Southwestern School of Medicine; Director, ProPath Dermatopathology, Dallas, Texas
Terry L Barrett, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Medical Association, American Society of Dermatopathology, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory
Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.